Recent News

• 02.09.2026 - MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
• 01.26.2026 - MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
• 01.08.2026 - MannKind Provides Business Updates and 2026 Growth Drivers
• 12.23.2025 - MannKind Shares FUROSCIX® Business Updates
• 12.01.2025 - MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
• 11.11.2025 - MannKind to Present at the Jefferies Global Healthcare Conference

Recent Filings

• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.08.2026 - 144 Report of proposed sale of securities
• 12.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.15.2025 - 8-K/A Current report
• 12.12.2025 - 144 Report of proposed sale of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.02.2025 - 144 Report of proposed sale of securities